Pieris Pharmaceuticals Net Income 2014-2021 | PIRS

Pieris Pharmaceuticals net income from 2014 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Pieris Pharmaceuticals Annual Net Income
(Millions of US $)
2020 $-37
2019 $-28
2018 $-27
2017 $-18
2016 $-23
2015 $-14
2014 $-10
2013 $0
Pieris Pharmaceuticals Quarterly Net Income
(Millions of US $)
2021-09-30 $-17
2021-06-30 $-15
2021-03-31 $-4
2020-12-31 $-14
2020-09-30 $-14
2020-06-30 $-5
2020-03-31 $-4
2019-12-31 $-4
2019-09-30 $-3
2019-06-30 $-12
2019-03-31 $-10
2018-12-31 $-12
2018-09-30 $-6
2018-06-30 $-0
2018-03-31 $-9
2017-12-31 $7
2017-09-30 $-7
2017-06-30 $-10
2017-03-31 $-8
2016-12-31 $-7
2016-09-30 $-6
2016-06-30 $-6
2016-03-31 $-4
2015-12-31 $-3
2015-09-30 $-4
2015-06-30 $-4
2015-03-31 $-4
2014-12-31 $-4
2014-09-30 $-2
2014-06-30 $-3
2014-03-31 $-1
2013-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.245B $0.029B
Pieris Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's drug technology consists of Anticalin(R) to treat cancer, severe asthma, anemia and other medical conditions. Pieris Pharmaceuticals, Inc. is based in Freising-Weihenstephan, Germany.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.036B 8.91
Bio-Rad Laboratories (BIO.B) United States $17.472B 35.46
QIAGEN (QGEN) Netherlands $11.101B 18.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.210B 0.00
Emergent Biosolutions (EBS) United States $2.527B 9.09
Arcus Biosciences (RCUS) United States $2.184B 0.00
Myovant Sciences (MYOV) United Kingdom $1.260B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.080B 0.00
Zymeworks (ZYME) Canada $0.522B 0.00
SQZ Biotechnologies (SQZ) United States $0.201B 0.00
Ambrx Biopharma (AMAM) United States $0.191B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.81